Prime medicine to present at h.c. wainwright 2nd annual bioconnect investor conference at nasdaq

Cambridge, mass., may 13, 2024 (globe newswire) -- prime medicine, inc. (nasdaq: prme), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that allan reine, m.d., chief financial officer of prime medicine, will participate in a fireside chat at the h.c. wainwright 2nd annual bioconnect investor conference at nasdaq on monday, may 20, 2024, at 4:30 p.m. et in new york, ny.
PRME Ratings Summary
PRME Quant Ranking